Concord Biotech delivered robust financial performance in the June 2026 quarter, with consolidated net profit rising 32.84% to ₹58.53 crore compared to ₹44.06 crore in the corresponding quarter of the previous year. According to reports from Business Standard, this significant profit growth demonstrates the company's strong operational efficiency and market positioning during the quarter. The company is positioned for a strong revenue rebound in Q1 FY27, supported by a 13-14% year-on-year rupee depreciation that provides a significant translation tailwind for its 45% export-denominated revenue.
The company's consolidated sales revenue increased 26.23% to ₹257.49 crore in Q1 FY2026, up from ₹203.99 crore in the same period last year. As reported by Business Standard, this revenue growth indicates strong demand for the company's products and effective market penetration strategies during the quarter. Management has guided for FY27 growth to exceed the historical 18% average, a target now bolstered by recent USFDA approvals for Tofacitinib and Mycophenolate Mofetil. The company's standalone revenue from operations growth of 27.71% YoY to ₹260.52 crore compared to ₹203.99 crore in the prior year, demonstrating robust operational momentum across both business segments.
Operating profit margin (OPM) improved to 31.99% in the June 2026 quarter compared to 30.10% in the corresponding quarter of the previous year. According to the financial data reported by Business Standard, this margin expansion reflects better cost management and operational efficiency during the quarter. The company's standalone profit after tax surged 43.74% YoY to ₹61.19 crore compared to ₹42.57 crore in Q1 FY26. Reported EBITDA margins are likely to improve sequentially from the 30.1% level seen in Q1 FY26, as the combined drag from injectable facility losses and Stellon Biotech setup costs continues to narrow. Management has identified a 1-1.5% reduction in power costs and operating leverage from the Stellon and injectable facilities as key margin drivers.
Concord Biotech secured USFDA approval for Tofacitinib Tablets (5 mg and 10 mg), unlocking commercialization access to an estimated $500 million US market. The company also successfully cleared Brazil's ANVISA inspection at the Limbasa API facility and completed joint Kenya (PPB) and Uganda (NDA) inspections at the Unit-II formulation facility. These regulatory clearances strengthen the company's position as an export-focused generic formulations player, with export revenues comprising approximately 45% of total income. The company also secured USFDA approval for Mycophenolate Mofetil Oral Suspension, targeting the US market size of approximately $30 million.
Concord Biotech stock has shown signs of recovery after falling over 20% from its record high of ₹1,803 reached on August 6, 2025. According to The Economic Times, the stock is currently trading above key moving averages and has broken out from a seven-month consolidation phase on weekly charts. Experts suggest buying the stock for a target above ₹1,500 levels in the next 3-4 weeks for short-term traders with high-risk profiles. The company invested ₹6.3 crore in a 12.6 MW wind-solar hybrid project to power the Limbasi API facility, which will satisfy captive energy requirements and lower long-term energy costs. With export revenues comprising approximately 45% of total income, the favorable translation impact of a depreciating rupee will act as an additional tailwind for earnings growth in FY27.
